Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 31, 2008 Brian Orelli	A Generic McMansion Mylan took an awfully big bite when it purchased Merck KGaA's generic-drug business last year, but so far it's proven that it can handle it.
The Motley Fool September 9, 2008 Brian Orelli	Sell Dey? Perhaps Another Day Generic-drug company Mylan decides to keep its specialty pharmaceutical subsidiary.
The Motley Fool October 30, 2009 Brian Orelli	It's Not As Frightening As It First Appears Dig a little, and you'll see that generic-drug maker Mylan is far from a copycat of its struggling branded-drug-making counterparts.
The Motley Fool April 30, 2009 Brian Orelli	A Great Generic Recovery After getting punished for taking on an acquisition, Mylan is doing pretty well.
The Motley Fool February 28, 2008 Brian Orelli	Mylan Almost Triples Revenue -- Big Deal Mylan's growth seems impressive last year, but that growth was all extrinsic, and it came at a cost.
The Motley Fool November 5, 2007 Brian Orelli	Last Look at Mini-Mylan An impending merger with Merck's KGaA's generic drug business should more than double revenue at Mylan.
The Motley Fool February 7, 2007 Brian Lawler	Mylan Adjusts to the Matrix The drugmaker got a bump from a new generic and settles in with its Matrix acquisition. Investors, take note.
The Motley Fool July 31, 2009 Brian Orelli	Two Pictures of a Drug Company Who should we believe? The FDA? Mylan's earnings report?
The Motley Fool July 30, 2007 Brian Orelli	Mega Mylan Is on Track Comparing year-over-year results for Mylan will continue to be complicated for the next year and a half or so. It's one merger down, one to go for the generic drug company. Investors, take note.
The Motley Fool February 20, 2009 Brian Orelli	Generic Synergies, Stellar Earnings Growth Mylan is working through its growing pains. The company doubled in size when it bought Merck KGaA's generic drug business, after it had already purchased Indian generic drugmaker Matrix Laboratories. In an instant, it became a global player.
The Motley Fool May 29, 2007 Brian Lawler	One Final Look at the Old Mylan With the Merck acquisition not expected to be accretive to earnings for at least two years, the question is if Mylan leveraged its financial health too far in its quest to get bigger and keep up in this buyout race.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool May 14, 2007 Brian Lawler	Mylan Goes on a Drug Binge The generic drugmaker makes a hefty acquisition, but it's hard to say at this point how good of a deal this is for shareholders.
The Motley Fool May 28, 2008 Brian Orelli	A Rough Quarter for Generic-Drug Makers Investors rocked the smaller companies the most.
The Motley Fool May 17, 2007 Rich Duprey	Foolish Forecast: My, Oh, Mylan The generic drug maker is set to report fourth-quarter 2007 financial results: Investors face the prospect of shareholder dilution, a cut in its credit rating, and the suspension of its dividend.
The Motley Fool June 11, 2008 Brian Orelli	Mylan Takes Generic Aim at Teva Mylan licenses a generic version of Teva's MS drug, Copaxone. Investors, take note.
The Motley Fool January 3, 2008 Brian Orelli	8 Generic-Drug Makers for 2008 Generic-drug makers can predict the growth of their industry, because it's written right in the patent-expirations column of the FDA's orange book. Here's a brief look at eight generic-drug makers worth closer scrutiny.
The Motley Fool May 12, 2004 Phil Wohl	Mylan's Big Break? The maker of generic pimple cream wants to lead the pack. Can it?
The Motley Fool July 27, 2009 Brian Orelli	Mylan Ruins It for Everyone If customers begin to mistrust generic drugs from Mylan or whoever -- fearing that the companies are putting profits above safety -- all generic-drug companies will be hurt.
The Motley Fool August 20, 2004 Ben McClure	Icahn Targets Mylan The billionaire's presence at the generic-drug maker Mylan could be bad news for management there, but good news for shareholders.
The Motley Fool May 16, 2007 Rich Duprey	Mylan's Costly Bid to Capture the Flag Its winning bid for a German Merck unit might be why it's falling behind in the generics game. Investors, take note.
The Motley Fool November 1, 2006 Brian Lawler	Mylan: Anything but Generic Revenues and earnings soar in the generic drug-maker's second quarter. Investors, take note.
The Motley Fool December 19, 2007 Brian Orelli	New Beta Blocker on the Crowded Street Forest and Mylan receive FDA approval for Bystolic. Investors, take note.
The Motley Fool August 17, 2011 Brian Orelli	Generic-Drug Makers Pay for Speed Lower margins -- faster.
The Motley Fool March 23, 2007 Brian Lawler	Mylan TKOs Pfizer Mylan launches a generic version of Pfizer's second-best selling drug. Investors, take note.
The Motley Fool June 30, 2009 Brian Orelli	Following the Pack to Future Returns Mylan's playing catch up, but there's room for more.
The Motley Fool September 29, 2010 Brian Orelli	A Mini-Teva in the Making Generic growth by Endo Pharmaceuticals.
The Motley Fool August 30, 2006 Brian Gorman	Mylan's Biogeneric Play The generic drugmaker buys an Indian firm to strengthen its long-term prospects. Investors, take note.
The Motley Fool February 28, 2007 Brian Lawler	Mylan Denied ... for Now The generic-drug maker loses its court battle to overturn the patents on Pfizer's No. 2 drug. This is a minor negative for Mylan, but for Pfizer, those extra six months of marketing exclusivity mean billions of dollars.
The Motley Fool November 21, 2008 Brian Orelli	Manufacturing Pain Johnson & Johnson has plenty of it.
The Motley Fool January 12, 2006 Stephen D. Simpson	Forest Keeps Reloading An agreement with Mylan Labs gives Forest access to a drug that could be launched in 2006. Investors, take note.
The Motley Fool February 9, 2006 Stephen D. Simpson	Mylan: Generic Drugs, Premium Price Mylan Labs is a fine company with a rich pipeline -- and an expensive stock.
The Motley Fool March 3, 2010 Brian Orelli	Judge's Ruling Has Brand and Generic Drugmakers Smiling A ruling on the patents on Merck's blood pressure medications Cozaar and Hyzaar benefited both Merck and the plaintiff in the suit, generic-drug maker Teva Pharmaceuticals. The defendant in the suit wasn't actually Merck but the Food and Drug Administration.
The Motley Fool September 4, 2007 Rich Duprey	Pain in Mylan's Future Competition for painkiller patch may prove to be a major pain for the generics maker Mylan. The stock has dropped precipitously from its highs, and while it's recovered some, its immediate outlook is cloudy.
Chemistry World May 1, 2015 Rebecca Trager	Generics firms in three-way takeover battle US-based Mylan is gunning for Irish rival Perrigo, but the deal is overshadowed by a bid for Mylan itself from Israel's powerhouse Teva.
The Motley Fool March 29, 2011 Brian Orelli	Much More Than a Generic Lawsuit The Supreme Court will decide generic-drug makers fate.
The Motley Fool April 7, 2010 Brian Orelli	Teva: Hold Until Things Turn Ugly Despite the drugmaker's recent success, its future looks precarious.
The Motley Fool November 23, 2004 Charly Travers	Mylan's "Three-Ring Circus" Carl Icahn is involved in the Mylan-King Pharmaceuticals so he can manipulate this situation to make money. And a lot of it.
The Motley Fool July 14, 2009 Brian Orelli	J&J Eats a Hard Quarter Tough year-over-year comparisons are no match for the health care giant.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
The Motley Fool January 19, 2010 Brian Orelli	Pfizer Gets Serious About Generics Serious, as in a potential $4-billion-purchase serious.
The Motley Fool March 16, 2005 Cliff Malings	Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition.
The Motley Fool November 26, 2008 Brian Orelli	Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better."
The Motley Fool September 30, 2009 Brian Orelli	Bigger Size, Lower Returns History is not on Merck and Schering's side.
The Motley Fool November 3, 2009 Brian Orelli	Nice Quarter, Teva. What Will You Buy Next? Branded or generic, it's always a tough call.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool December 3, 2007 Brian Orelli	Nebivolol's Almost Approvable Letter Forest and Mylan get an approvable letter for Nebivolol.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool June 22, 2007 Tim Beyers	Who's Buying Now? Sometimes, insiders are buying for all the right reasons. Who's at it this week? Mylan Laboratories... Cherokee... Luminent Mortgage... MVC Capital... etc.